主要文件

查看所有文档

P8396

Piperacillin sodium salt

Name: Piperacillin sodium salt
Brand: SIGMA

penicillin analog

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₃H₂₆N₅NaO₇S

化学文摘社编号:

59703-84-3

分子量:

539.54

UNSPSC Code:

51282423

NACRES:

NA.85

PubChem Substance ID:

329820325

EC Number:

261-868-6

Beilstein/REAXYS Number:

5373920

MDL number:

MFCD00917471

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

Quality Level

200

form

powder

solubility

H₂O: soluble 50 mg/mL

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

SMILES string

[Na+].CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)c4ccccc4)C(=O)C1=O

InChI

1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1

InChI key

WCMIIGXFCMNQDS-IDYPWDAWSA-M

说明

General description

Chemical structure: β-lactam

Application

Piperacillin is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is derived from ampicillin. It has been used in pharmacokinetic studies in order to optimize antimicrobial therapy in patients with sepsis. It is used to study piperacillin hypersensitivity reactions and to study multidrug-resistant organisms.

Biochem/physiol Actions

Piperacillin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins (PBPs), which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Piperacillin may interfere with autolysin inhibitors.

Packaging

1g,5g,10g

Other Notes

Keep container tightly closed in a dry and well-ventilated place.Keep in a dry place.

Still not finding the right product?

Explore all of our products under

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.

Grace C Lee et al.

Clinical therapeutics, 34(12), 2297-2300 (2012-12-01)

Studies evaluating the outcomes of an extended-infusion (EI) piperacillin-tazobactam dosing strategy in specific cohorts of critically ill patients are lacking. A retrospective, pre-implementation and post-implementation study of 148 critically ill patients was conducted to compare EI and traditional infusion piperacillin-tazobactam.

Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.

João Gonçalves-Pereira et al.

PloS one, 7(11), e49845-e49845 (2012-11-28)

The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients

Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.

S Christian Cheatham et al.

International journal of antimicrobial agents, 41(1), 52-56 (2012-12-12)

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Fourteen hospitalised patients weighing >120kg received piperacillin/tazobactam 4.5 g every 8 h (q8h) or 6.75 g q8h infused over

查看所有相关文献

全球贸易项目编号

货号	GTIN
P8396-1G	04061834401377
P8396-10G	04061834401360
P8396-5G	04061834401384